Dr. Michael J. Downing, MD
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 40
Licensed in Texas since 1992, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: University of Texas Medical School at Houston
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
TX license J1082 (first issued 1992; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 40
- Services billed
- 438
- Patients’ average age
- 62
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 10-19 minutes | 277 | 44 |
| Psychotherapy with evaluation and management visit, 30 minutes | 255 | 43 |
| Psychotherapy with evaluation and management visit, 45 minutes | 22 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clozapine Other prescribers in Dallas, TX | 139 |
| Clonazepam Other prescribers in Dallas, TX | 73 |
| Lorazepam Other prescribers in Dallas, TX | 58 |
| Olanzapine Other prescribers in Dallas, TX | 50 |
| Lamotrigine Other prescribers in Dallas, TX | 35 |
| Invega Trinza (paliperidone palmitate) Other prescribers in Dallas, TX | 34 |
| Vraylar (cariprazine hcl) Other prescribers in Dallas, TX | 30 |
| Trazodone Hcl Other prescribers in Dallas, TX | 28 |
| Divalproex Sodium Er (divalproex sodium) Other prescribers in Dallas, TX | 26 |
| Aripiprazole Other prescribers in Dallas, TX | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 37 payments worth $847 in total to this clinician.
| Food and Beverage | $847 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 25 industry-funded studies in 2025, from 9 companies. The companies reported $914,453 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms
Axsome Therapeutics, Inc. - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06683508 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
AbbVie Inc. · Completed · NCT06605599 - A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT06603571 - A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06230523 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO)
AbbVie Inc. - TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy
Takeda Pharmaceuticals U.S.A., Inc. - LX9211.1-204-DPN
Lexicon Pharmaceuticals, Inc. - A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Recruiting · NCT06143956
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.